THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt as to what action you should take, you are recommended to seek your own financial advice from your stockbroker or other independent adviser authorised under the Financial Services and Markets Act 2000.

If you have sold or transferred all of your shares in BATM Advanced Communications Ltd., please forward this document, together with the accompanying documents, as soon as possible either to the purchaser or transferee or to the person who arranged the sale or transfer so they can pass these documents to the person who now holds the shares.

Please note that this document sets out different voting processes for securities traded on the London Stock Exchange and for securities traded on the Tel-Aviv Stock Exchange. You must follow the correct process applicable to the securities you hold. If you hold multiple types of securities, you must follow a different process for each portion of your holding (see note 4 below in the Notes to the Notice of Annual General Meeting for further information regarding the process).

BATM ADVANCED COMMUNICATIONS LTD.

Notice of Annual General Meeting

of 23 December 2026

Chairman's letter

18 November 2026

Dear Shareholder,

Annual General Meeting

I enclose the notice of the Annual General Meeting ("**AGM**" or "**the Meeting**") of BATM Advanced Communications Ltd. (or "**the Company**"), which is to be held at the Company's offices at 4 Ha'harash Street, Nave Ne'eman Industrial Area, building E, 12th floor, P.O.B. 7318, 4524075 Hod Hasharon, Israel on Wednesday 23 December 2026 at 12.00 p.m. Israel-time (10.00 a.m. UK-time) (the "**Notice**").

In order to enable shareholder engagement and participation for those unable to physically attend the Meeting, shareholders will be able to access the Meeting via videoconference.

PLEASE NOTE, shareholders will not be able to vote at the Meeting via the videoconference. Shareholders attending the Meeting via videoconference are therefore strongly encouraged to submit their vote in advance of the AGM, in accordance with the Notes to the Notice of Annual General Meeting set out below. To register to attend the AGM via videoconference or to submit a question, please email yair.livneh@batm.com, stating your full name, at your earliest opportunity and no later than 72 hours before the AGM.

Recommendation

The Board believes that all the resolutions to be considered at the AGM are in the best interests of the Company and are most likely to promote the success of the Company for the benefit of its members as a whole, and the directors (other than myself with regards to resolution 11) recommend that you vote in favour of all the proposed resolutions.

Yours sincerely,

Gil Sharon
Chairman

Notice is hereby given that the Annual General Meeting ("AGM" or the "Meeting") of BATM Advanced Communications Ltd. ("BATM" or the "Company") will be held at the Company's offices at 4 Ha'harash Street, Nave Ne'eman Industrial Area, building E, 12th floor, Hod Hasharon, Israel on Wednesday 23 December 2026 at 12.00 p.m. Israel-time (10.00 a.m. UK-time).

The purpose of the AGM is to receive and discuss the Company's audited annual accounts for the year ended 31 December 2025 and the directors' report thereon and to consider and, if thought fit, pass the resolutions detailed below.

RESOLUTIONS

I. Annual Report, Accounts and Re-appointment of Auditors

1. To receive the Company's audited annual accounts for the financial year ended 31 December 2025 together with the directors' report and the auditor's report on those accounts.

2. To approve the report of the Company's Remuneration Committee for the financial year ended 31 December 2025 together with the auditor's report on the auditable part of the remuneration report.

3. To re-appoint the auditors of the Company (Brightman Almagor Zohar & Co., a Firm in the Deloitte Global Network) as external auditors until the conclusion of the next Annual General Meeting of the Company, and to authorise the Board of Directors to fix the auditor's remuneration for such period.

II. Election and Re-election of Directors

4. To re-elect Mr. Gil Sharon to the Board of Directors of the Company until the next Annual General Meeting of the Company (Note A).

5. To re-elect Mr. Moti Nagar to the Board of Directors of the Company until the next Annual General Meeting of the Company (Note A).

6. To re-elect Mr. Leor Miles to the Board of Directors of the Company until the next Annual General Meeting of the Company (Note A).

7. To re-elect Dr. Avigdor Shafferman to the Board of Directors of the Company until the next Annual General Meeting of the Company (Note A).

8. To re-elect Dr. Shmuel Ben Zvi to the Board of Directors of the Company until the next Annual General Meeting of the Company (Note A).

9. Subject to the appointment of Mr. Haim Dor to the Board of Directors of the Company as per the shareholders' resolution at the General Meeting of 24 September 2026 becoming effective prior to the AGM - to re-elect Mr. Dor to the Board of Directors of the Company until the next Annual General Meeting of the Company (Note A).

III. Disapplication of pre-emption rights

10. That the directors will be generally authorised and empowered to allot equity securities pursuant to the authority conferred by article 10B of the Company's articles of association

as if article 10A (existing shareholders' right of pre-emption) did not apply to the allotment provided that this power shall:

10.1 refer to the allotment of equity securities or sale of treasury shares up to such number of equity securities or treasury shares that equal 10% of the issued and allotted share capital of the Company;

10.2 refer to the allotment of equity securities or sale of treasury shares (otherwise than under paragraph 10.1 above) up to a nominal amount equal to 20% of any allotment of equity securities or sale of treasury shares from time to time under paragraph 10.1 above, such authority to be used only for the purposes of making a follow-on offer that the Board of the Company determines to be of a kind contemplated by paragraph 3 of Section 2B of the Statement of Principles on Disapplying Pre-Emption Rights most recently published by the Pre-Emption Group prior to the date of this notice;

10.3 be limited to the allotment of equity securities or sale of treasury shares up to such number of equity securities or treasury shares that equal 10% of the issued and allotted share capital of the Company, such authority to be used only for the purposes of financing (or refinancing, if the authority is to be used within 12 months after the original transaction) a transaction that the Board of the Company determines to be either an acquisition or a specified capital investment of a kind contemplated by the Statement of Principles on Disapplying Pre-Emption Rights most recently published by the Pre-Emption Group prior to the date of this notice;

10.4 be limited to the allotment of equity securities or sale of treasury shares (otherwise than under paragraph 10.3 above) up to a nominal amount equal to 20% of any allotment of equity securities or sale of treasury shares from time to time under paragraph 10.3 above, such authority to be used only for the purposes of making a follow-on offer that the Board of the Company determines to be of a kind contemplated by paragraph 3 of Section 2B of the Statement of Principles on Disapplying Pre-Emption Rights most recently published by the Pre-Emption Group prior to the date of this notice; and

10.5 such disapplication to expire on the earlier of the close of business on the date falling fifteen months after the passing of this resolution (unless renewed, varied or revoked by the Company prior to or on that date), or on the date of the next Annual General Meeting of the Company save, however, that the Company may, before such expiry make an offer or agreement that would or might require equity securities to be allotted after such expiry and the Directors may allot equity securities in pursuance of any such offer or agreement notwithstanding that the power conferred by this resolution has expired.

(see Note B)

IV. Remuneration

11. To approve that the remuneration for the role of Chairman of the Board of the Company will be an annual salary of USD 150,000, effective retroactively from 1 January 2026 (Note C).

Resolutions 1 to 9 and 11 are being proposed as ordinary resolutions, and resolution 10 is being proposed as a special resolution.

Explanatory Notes to the Resolutions

Note A:

1. Mr. Gil Sharon has over 30 years' experience in the telecommunications industry. He is currently Chairman of IBC, an Israeli fibre optic telecom company. Prior to IBC, he was Executive Chairman of Bezeq The Israeli Telecommunications Corporation Ltd (TASE: BEZQ), the largest telecommunications group in Israel, and Chairman of its subsidiaries: Pelephone, a mobile network operator; Yes, a television and internet service provider; and Bezeq International, a business internet services, international communication, integration and IT solutions company. Other roles have included Chairman, CEO and co-investor of Golan Telecom, and CEO of Pelephone. Mr. Sharon has extensive experience in providing strategic business consulting to boards and executives, particularly within the telecommunication and technology sectors. He was elected as a Director of the Board in December 2025, and appointed Chairman later that month.

2. Mr. Moti Nagar has been the CEO of BATM since 1 January 2023, having been the CFO since 2015. During his time at BATM, Mr. Nagar has been instrumental in driving the business' development, including leading several M&A transactions, the Group's IPO on TASE and, since his appointment as CEO, delivering a renewed strategy. Prior to BATM, Mr. Nagar held several senior positions at Deloitte, which he joined in 2005. As a Senior Manager, Mr. Nagar was responsible for handling the accounts of leading corporate clients in Israel and overseas, with companies traded on the LSE, NASDAQ and TASE as well as private businesses operating in a range of sectors. Mr. Nagar is a member of the Managing Board of the Israeli Association of Publicly Traded Companies, a non-profit organisation representing hundreds of companies listed on the Tel Aviv Stock Exchange and other stock exchanges throughout the world. Mr. Nagar graduated in Business Management and Accounting and qualified as an Israeli Certified Public Accountant (CPA, Israel) in 2008. He also holds an MBA in Financial Management from Tel Aviv University. He was re-elected as a Director of the Board in December 2025. Mr. Nagar brings to the role of CEO business management and accounting skills and experience he gathered from his years as CFO at BATM and as an audit manager to international companies. As CEO of BATM his core skills include business leadership and management, international business operations and strategy, business finance, M&A experience, stakeholder and shareholder management, forward thinking and calculated risk management.

3. Mr. Leor Miles was appointed CFO of BATM in June 2025, bringing over 15 years' experience in financial management for public and private companies operating globally primarily in the technology industry, including serving as VP Finance of BATM from 2015-2021. Mr. Miles joined BATM from Kenes Group where, as Group CFO, he oversaw financial operations, including investments, cash management, risk management, insurance, M&A, taxation and financial strategy, for the global operations across 18 locations on four continents. Other experience includes being Director of Finance for Abra Information Technologies Ltd., a TASE-listed provider of IT services and solutions, and its subsidiaries in the US and Israel. Mr. Miles is an Israeli Certified Public Accountant who commenced his

career as an accountant at PwC, where he performed company audits in accordance with US GAAP and IFRS standards. He holds a BA in Accounting and Economics and an MA in Accounting from Bar Ilan University. Mr. Miles has senior finance experience at businesses with global operations and with public company obligations. He also has familiarity with BATM due to his previous employment. He was elected as a Director of the Board in December 2025.

4. Dr. Avigdor Shafferman had an established career at the Israel Institute for Biological Research, a leading governmental applied research institute specialising in the fields of biology, medicinal chemistry and environmental sciences, where he worked for almost 40 years. He is a recipient of several prestigious scientific awards and author of over 200 scientific papers. Most recently, from 1995 until his retirement in 2013, he was General Director of the organisation. Other roles have included serving as a visiting professor in the University of California, San Diego at the biology department as well as a visiting senior research scientist at various leading research institutions in the United States in various medical areas. Dr. Shafferman holds a Ph.D. in physical chemistry from the Hebrew University of Jerusalem. Dr. Shafferman is an influential scientist with experience in top-management and international cooperation. He has served as a non-executive director of the Company since 2022, and the Company has classified him as an Independent Director (as defined under Israeli law). He was re-elected as a Director of the Board in December 2025.

5. Dr. Shmuel (Muli) Ben Zvi has extensive executive and board experience across multiple industries, including nine years as a director of Bank Leumi, the largest banking corporation in Israel, and being elected Chairman of the board in October 2023 for the final year of his tenure. At Bank Leumi, he was a member of the board's audit, risk management, credit, technology and strategy committees. Dr. Ben Zvi is currently Chairman of Revolut Israel, a digital bank and an entity of the global Revolut Group Holdings Ltd, and a director of Protalix Biotherapeutics (NYSE American: PLX). He was previously a director of Sol-Gel Technologies (NASDAQ: SLGL) and VBL Therapeutics (NASDAQ: VBLT). From 2004 to 2014, he held a number of managerial positions at Teva Pharmaceuticals (NASDAQ and TASE: TEVA), including Vice President of Strategy and Vice President of Finance. Dr. Ben Zvi brings to the Board extensive experience in finance and strategy management as well as a deep understanding of corporate governance, including for international public companies. He has served as a non-executive director of the Company since December 2024, and the Company has classified him as an Independent Director (as defined under Israeli law). He was re-elected as a Director of the Board in December 2025.

6. Mr. Sharon, Mr. Nagar, Mr. Miles, Dr. Shafferman and Dr. Ben Zvi were appointed or re-appointed as directors at the 2025 AGM until the then-next AGM of the Company. The shareholders are requested to re-appoint each of them for an additional term with such term to expire at the next AGM of the Company. Their re-election requires a simple majority, as set out under sections 59 and 85 of the Israeli Companies Law and article 39 of the Company's Articles of Association.

   In addition to Mr. Sharon, Mr. Nagar, Mr. Miles, Dr. Shafferman and Dr. Ben Zvi, there are two "External Directors" (as that term is defined under Israeli Companies' Law) of the Board - Prof. Varda Shalev and Mrs. Ayala Hakim. External Directors are appointed to 3-year terms. Prof. Shalev's 3-year term (third and last term) ends in 2027 and Mrs. Hakim's 3-year term (first term) ends in 2028.

7. On 24 September 2026, the shareholders approved the election of Mr. Haim Dor to the Board of Directors subject to the completion of the sale of non-core businesses and Company shares

to Mr. Dor, effective from the date of such completion until the following AGM of the Company. If such completion happens prior to the date of the AGM, it will be effective until the AGM, and in such case the shareholders are requested to re-appoint Mr. Dor for an additional term with such term to expire at the next AGM of the Company. As noted in the Company's announcement of 17 November 2026, it is intended that such completion will occur on, or before, 10 December 2026, ahead of the Meeting. If completion does not occur by the AGM, this resolution will be withdrawn at the AGM. Mr. Dor's re-election requires a simple majority, as set out under sections 59 and 85 of the Israeli Companies Law and article 39 of the Company's Articles of Association.

Mr. Dor has over 35 years' experience investing and developing companies across various industries. During the past 20 years, he has focused primarily on the healthcare sector. Over the last decade, Mr. Dor was the founder and a significant shareholder of Raphael Hospitals Ltd. He played a leading role in the planning, establishment, and operation of Raphael Hospital, which was founded in Tel Aviv as a modern and innovative institution combining advanced technologies, leading medical teams, and a broad range of surgical and medical services. Mr. Dor has extensive experience in strategic investments and business development, particularly within the healthcare sector.

Note B:

8. The proposed resolution is to allow the Company to disapply the pre-emption rights in the Company's articles of association for up to 10% of the allotted and issued share capital of the Company for general purposes, together with a further 20% of the relevant offer for a follow-on offer, and 10% for the purposes of an acquisition or specified capital investment in accordance with the Pre-Emption Group's most recent statement of principles, together with a further 20% of the relevant offer for a follow-on offer. This will expire on the earlier of the date falling fifteen months after the passing of the resolution and the Company's next annual general meeting. If passed it will give the directors power to allot equity securities (as defined by section 560 of the United Kingdom Companies Act 2006) and to sell treasury shares for cash without first offering them to existing shareholders in proportion to their existing holdings. The maximum amount will be such number of shares that represent no more than 24% of the issued and allotted share capital of the Company. This proposed resolution is in line with guidance by the Investment Association, the Pre-Emption Group's Statement of Principles and the template resolutions published by the Pre-Emption Group in 2022. This resolution requires the special majority set forth in the definition of "Special Resolution" in article 1 of the Company's Articles of Association.

Note C:

9. Pursuant to the Israeli Companies Law, the terms of office of a director, including the Chairman of the Board, require the approval of the Remuneration Committee, the Board of Directors and the general meeting, and the Company requires the approval of shareholders for any remuneration of its non-executive directors that is greater than the statutory remuneration for external directors.

10. The current remuneration for the role of Chairman of the Board is an annual salary of USD 100,000, which was approved by shareholders at the AGM held in December 2024, being the

annual salary originally approved by shareholders on 21 December 2022 in respect of the previous Chairman of the Board. This resolution seeks shareholder approval to update the remuneration for the role to an annual salary of USD 150,000, with effect from 1 January 2026, payable in four equal quarterly instalments. The incremental amount in respect of the period from 1 January 2026 until the Meeting will be paid in a single payment following the Meeting, subject to the passing of this resolution.

11. Mr. Gil Sharon was elected to the Board in December 2025 and was appointed Chairman later that month. The proposed update reflects the scope and demands of the role at this stage of the Company's strategic transformation, in which the Board and management are leading the repositioning of the Group as a focused networking and cybersecurity company; the significant time and availability that the Chairman devotes to the role, including active support of management; and the experience, expertise and industry relationships that the Chairman contributes to the Company, including in business development. In reaching its recommendation, the Remuneration Committee also had regard to the fact that the current salary for the role has remained unchanged since it was first approved in December 2022, and to comparative considerations regarding remuneration of chairmen of comparable companies.

12. The remuneration proposed under this resolution is a fixed cash salary and does not include any performance-based or equity component.

13. The proposed remuneration was approved by the Remuneration Committee and by the Board of Directors (with Mr. Sharon not participating).

14. As the proposed remuneration is in accordance with the Remuneration Policy, this resolution requires a simple majority of the votes cast at the Meeting, in accordance with section 273 of the Israeli Companies Law.

Dated: 18 November 2026

By order of the Board
Moti Nagar

Chief Executive Officer

Company number: 52-0042813

Registered office: 4 Ha'harash Street, Nave Ne'eman, PO Box 7318, Hod Ha'sharon, 4524075 Israel.

Notes to the Notice of Annual General Meeting

1. Only those members registered on the Company's register of members at close of business (Israel-time) on 18 November 2026 (the "**Record Date**") shall be entitled to attend and vote at the Meeting. Changes to the register of members after the Record Date shall be disregarded in determining the rights of any person to attend and vote at the Meeting.

2. Information regarding the Meeting is available and can be found on the Company's website at www.batm.com.

3. Quorum and adjourned meeting – the quorum shall be two or more shareholders present in person or by proxy. If such quorum is not present within one hour from the time scheduled for the Meeting, the Meeting will be adjourned for one week (to the same day, time and place). Any two members present in person or by proxy at the adjourned meeting, shall be deemed a quorum.

4. Enclosed with this document is (1) a form of proxy for holders of certificated securities admitted to trading on the London Stock Exchange (a "Form of Proxy"), (2) a form of direction for holders of uncertificated securities (i.e. Depositary Interests) representing ordinary shares admitted to trading on the London Stock Exchange (the "Form of Direction"), and (3) a form of proxy for holders of the Company's shares listed on the Tel-Aviv Stock Exchange (a "Form of Proxy to a TASE Member"). Please note that this document sets out different processes for securities admitted to trading on the London Stock Exchange and securities traded on the Tel-Aviv Stock Exchange. You must follow the correct process applicable to the securities you hold. If you hold multiple types of securities, you must follow a different process for each portion of your holdings.

5. **Shareholders holding through the London Stock Exchange** - If you are a member of the Company at the time set out in Note 1 above, you are entitled to appoint a proxy to exercise all or any of your rights at the Meeting. A proxy need not be a member of the Company but must attend the Meeting to represent you. Details of how to appoint your proxy are set out in the notes to the proxy form. **In order to be valid, proxy forms must be lodged at either MUFG Corporate Markets (the Company's registrar), at its address (MUFG Corporate Markets, PXS 1, Central Square, 29 Wellington Street, Leeds LS1 4DL, United Kingdom) or at the registered office of the Company in Israel marked for the attention of the General Counsel not less than 48 hours prior to the Meeting. A Form of Proxy appears below. Alternatively, you may submit your proxy electronically via the Investor Centre, a free app provided by MUFG Corporate Markets.** It allows you to securely manage and monitor your shareholdings in real time, take part in online voting, keep your details up to date and more. The same voting deadline of 48 hours before the time of the Meeting applies. The app is available to download on both the Apple App Store and Google Play, or by scanning the relevant QR code below, or can be accessed via a web browser at: https://uk.investorcentre.mpms.mufg.com/. If you need help with voting online, please contact our registrar, MUFG Corporate Markets, by email at shareholderenquiries@cm.mpms.mufg.com, or on 0371 664 0300. Calls are charged at the standard geographic rate and will vary by provider. Calls outside the United Kingdom will be charged at the applicable international rate. Lines are open between 9.00 a.m. – 5.30 p.m., Monday to Friday excluding public holidays in England and Wales.



6. In the case of a member which is a corporation, the proxy (or any related document) should be given under its common seal or under the hand of an officer or attorney duly authorised in writing. Any power of attorney or any other authority under which the Form of Proxy is

signed (or a duly certified copy of such party or authority) must be included with the Form of Proxy.

7. In the case of joint holders, where more than one of the joint holders purports to appoint a proxy, only the appointment submitted by the most senior holder will be accepted. Seniority is determined by the order in which the names of the joint holders appear in the Company's register of members in respect of the joint holding (the first-named being the most senior).

8. A corporation which is a shareholder can appoint one or more corporate representatives who may exercise, on its behalf, all its powers as a shareholder provided that no more than one corporate representative exercises powers over the same share.

9. To change your proxy instructions, simply submit a new proxy appointment using the methods set out above. Note that the cut-off time for receipt of proxy appointments (see above) also applies in relation to amended instructions. Any amended proxy appointment received after the relevant cut-off time will be disregarded.

   If you submit more than one valid proxy appointment, the appointment received last before the latest time for the receipt of proxies will take precedence.

   In order to revoke a proxy instruction, you will need to inform the Company in writing by sending a signed hard copy notice clearly stating your intention to revoke your proxy appointment to MUFG Corporate Markets at the address referred to above or to the registered office of the Company in Israel marked for the attention of the General Counsel. In the case of a member which is a corporation, the revocation notice must be executed under its common seal or signed on its behalf by an officer or attorney duly authorised in writing, and any power of attorney or other authority under which it is signed (or a duly certified copy of such power or authority) must be included with the revocation notice. In either case, the revocation notice must be received not less than 48 hours prior to the Meeting. If you attempt to revoke your proxy appointment but the revocation is received after this time, your original proxy appointment will remain valid.

10. A vote withheld is not a vote in law, which means that the vote will not be counted in the calculation of votes for or against the resolution. If no voting indication is given, your proxy will vote or abstain from voting at their discretion. Your proxy will vote (or abstain from voting) as they think fit in relation to any other matter that is put before the Meeting.

11. In the case of holders of Depositary Interests representing shares in the Company, a Form of Direction must be completed in order to direct MUFG Corporate Markets Trustees (Nominees) Limited, the Depositary, to vote on the holder's behalf at the Meeting (in person or by proxy) or, if the Meeting is adjourned, at the adjourned meeting. **In order to be effective, a completed and signed Form of Direction (and any power of attorney or other authority under which it is signed) must be delivered to MUFG Corporate Markets, PXS 1, Central Square, 29 Wellington Street, Leeds LS1 4DL, United Kingdom by no later than 72 hours before the time fixed for the Meeting or any adjourned meeting.** A Form of Direction appears below.

12. If you are a holder of Depositary Interests, your shares are held on your behalf in the name of MUFG Corporate Markets Trustees (Nominees) Limited, who are the registered shareholder. You can tell them how you want the votes in respect of your shares to be cast at the Meeting and any adjournment(s) thereof, by utilising the CREST electronic proxy appointment service as per the procedures described in the CREST Manual (available from

www.euroclear.com). CREST personal members or other CREST sponsored members, and those CREST members who have appointed a voting service provider(s), should refer to their CREST sponsor or voting service provider(s), who will be able to take the appropriate action on their behalf.

In order for an instruction made using the CREST service to be valid, the appropriate CREST message (a CREST Proxy Instruction) must be properly authenticated in accordance with Euroclear UK & International Limited's specifications and must contain the information required for such instruction, as described in the CREST Manual (available via www.euroclear.com). The message, regardless of whether it constitutes a new instruction or is an amendment to the instruction given previously must, in order to be valid, be transmitted so as to be received by the Company's registrars (ID: RA10) by no later than 72 hours before the time fixed for the Meeting or any adjourned meeting. For this purpose, the time of receipt will be taken to be the time (as determined by the time stamp applied to the message by the CREST Application Host) from which the issuer's agent is able to retrieve the message by enquiry to CREST in the manner prescribed by CREST. After this time, any change of instructions through CREST should be communicated to the Depositary through other means.

CREST members and, where applicable, their CREST sponsors or voting service providers should note that Euroclear UK & International Limited does not make available special procedures in CREST for any particular messages. Normal system timings and limitations will therefore apply in relation to the input of CREST Proxy Instructions. It is the responsibility of the CREST member concerned to take (or, if the CREST member is a CREST personal member or sponsored member or has appointed a voting service provider(s), to procure that his CREST sponsor or voting service provider(s) take(s)) such action as shall be necessary to ensure that a message is transmitted by means of the CREST system by any particular time. In this connection, CREST members and, where applicable, their CREST sponsors or voting service providers are referred, in particular, to those sections of the CREST Manual concerning practical limitations of the CREST system and timings (www.euroclear.com).

The Company may treat as invalid a CREST Proxy Instruction in the circumstances set out in Regulation 35(5)(a) of the Uncertificated Securities Regulations 2001 (as amended).

13. The Depositary will appoint the Chair of the Meeting as its proxy to cast its votes. The Chair of the Meeting may also vote or abstain from voting as they think fit on any other business (including amendments to resolutions) that may properly come before the Meeting. The 'Abstain' option is provided to enable you to abstain from voting on the resolutions. However, it should be noted that an 'Abstain' is not a vote in law and will not be counted in the calculation of the proportion of the votes 'For' and 'Against' a resolution.

14. Depositary Interest holders wishing to attend the Meeting should contact the Depositary at MUFG Corporate Markets, Central Square, 29 Wellington Street, Leeds, LS1 4DL or by emailing Nominee.Enquiries@cm.mpms.mufg.com by no later than 72 hours before the time fixed for the Meeting or any adjourned meeting.

15. **Shareholders holding through the TASE** - Shareholders may vote their shares by appointing the TASE Member (bank, broker or other nominee that is admitted as a member of the TASE) through which they hold their shares as "proxies" to vote on their behalf, and they must direct the TASE Member on how to vote their shares. A duly executed Form of Proxy must be received by the TASE Member no later than 10.00 a.m. (Israel-time) on 16 December 2026, in order to be counted in the vote to be held in the Meeting. A shareholder's returned proxy may be revoked at any time prior to its exercise by giving written notice to

the TASE Member of such revocation, sending a duly executed Form of Proxy bearing a later date, no later than 10.00 a.m. (Israel-time) on 16 December 2026, requesting the return of the original Form of Proxy. The vote at the Meeting shall be carried out by the TASE Clearing House. The TASE Member shall direct the TASE Clearing House on how to vote the shares held by it, according to the TASE Clearing House by-laws, and submit to the TASE Clearing House a summary of the final results of all the proxies received by it and which it requests the TASE Clearing House to vote in its name, including the information required in the Form of Proxy regarding personal interests of the shareholders, if they are senior officers in the Company or controlling shareholders in the Company or a foreign institutional client, joint investment fund manager or trust fund, by no later than 2.00 p.m. (Israel-time) on 16 December 2026. A shareholder whose ordinary shares are registered with a TASE Member and are not registered on the Company's shareholder register is entitled to receive from the TASE Member who holds the ordinary shares on the shareholder's behalf, by email, for no charge, a link to the text of the Form of Proxy and to the position statements posted on the Israel Securities Authority website unless the shareholder has notified that he or she is not so interested; provided that the notice was provided with respect to a particular securities account prior to the Record Date. Beneficial owners who hold ordinary shares through TASE Members, or the TASE, would ordinarily be able to attend the Meeting by presenting a certificate signed by the TASE Member through which the shares are held, which complies with the Israel Companies Regulations (Proof of Ownership for Voting in General Meetings)-2000 as proof of ownership of the shares, or they may send such certificate to the Company's registered office prior to the Meeting. However, beneficial owners who hold ordinary shares through TASE Members will not be able to vote at the Meeting in person and will have to follow the voting instructions detailed in this sub-section 15 and in the Form of Proxy.

16. Appointment of a proxy does not preclude you from attending the Meeting and voting in person (except for shareholders whose shares are listed on the TASE, to whom sub-section 15 herein shall apply).

17. **Attendance by videoconference** - Shareholders may attend the Meeting by videoconference. To register, please email yair.livneh@batm.com stating your full name (and, if applicable, the name in which your shares are held) no later than 72 hours before the time fixed for the Meeting. Registered shareholders will be sent the videoconference link and joining instructions by email before the Meeting. Shareholders attending by videoconference will not be able to ask questions during the Meeting. Any questions relating to the business of the Meeting must be submitted in advance by email to yair.livneh@batm.com no later than 72 hours before the time fixed for the Meeting. Shareholders attending by videoconference will not be able to vote at the Meeting and are strongly encouraged to vote in advance in accordance with these Notes. Attendance by videoconference does not constitute attendance in person or by proxy, and shareholders attending only by videoconference will not be counted towards the quorum.

18. The Company will answer at the Meeting any question relating to the business being dealt with that you submit in advance as detailed in note 17 above, unless:

    18.1 answering the question would interfere unduly with the preparation for the Meeting or involve the disclosure of confidential information;

    18.2 the answer has already been given on a website in the form of an answer to a question; or

18.3 it is undesirable in the interest of the Company or the good order of the Meeting that the question be answered.

19. As at 17 November 2026, being the last practicable date prior to the publication of this notice, the Company's issued share capital comprised 441,369,184 ordinary shares of 0.01 NIS each, including 4,495,000 ordinary shares held in treasury and 96,794,500 shares held by a subsidiary. Each ordinary share (other than those held in treasury or by a subsidiary) carries the right to one vote at a general meeting of the Company and, therefore, the total number of voting rights in the Company as at 17 November 2026 is 340,079,684.

20. If you hold securities traded on the London Stock Exchange and do not have a Form of Proxy or Form of Direction and believe that you should have one, or if you require additional forms, please contact MUFG Corporate Markets via email at shareholderenquiries@cm.mpms.mufg.com or on 0371 664 0300 if calling from the UK or +44 (0)371 664 0300 if calling from outside the UK. Calls are charged at the standard geographic rate and will vary by provider. Calls outside the United Kingdom will be charged at the applicable international rate. Lines are open between 09:00 - 17:30, Monday to Friday excluding public holidays in England and Wales.

21. You may not use any electronic address provided either:

21.1 in this notice of Annual General Meeting; or

21.2 any related documents (including the Chairman's letter and proxy form)

to communicate with the Company for any purposes other than those expressly stated.

22. Information concerning the Company may be found on its website at www.batm.com.

23. The following documents will be available for inspection at **the registered office of the Company** from 18 November 2026 until the time of the Meeting and at the Meeting venue itself for at least 15 minutes prior to the Meeting until the end of the Meeting:

- A copy of the current Company's articles of association
- A copy of the current Company's Remuneration Policy

THIS PAGE IS INTENTIONALLY LEFT BLANK

Form of Proxy

(for holders of securities listed on the London Stock Exchange)

For use at the Annual General Meeting of BATM Advanced Communications Ltd. To be convened At 12.00 p.m. Israel-time (10.00 a.m. UK-time) on 23 December 2026 at the Company's offices at 4 Ha'harash Street, Nave Ne'eman Industrial Area, building E, 12th floor, Hod Hasharon, Israel

I/We ……

of ……

being a member of the Company hereby appoint ……..……/ the Chairman of the meeting to act as my/our proxy and to vote for me/us as indicated below with an "X" at the Annual General Meeting of the Company convened for 23 December 2026 at 12.00 p.m. Israel-time (10.00 a.m. UK-time) and at any adjournment.

Date …… Signed ……

Please indicate how you wish to vote with an "X" in the appropriate box opposite the resolution. If no specific indication as to voting is given, your proxy will vote or abstain from voting at their discretion. Your proxy will vote (or abstain from voting) as they think fit in relation to any other matter which is put before the meeting.

No.	**Resolution**	**Your vote**		
		For	**Against**	**Abstain**
1.	To receive the annual accounts and directors' and auditor's reports thereon			
2.	To approve the report of the Remuneration Committee			
3.	To re-appoint the auditors of the Company and authorise the Board of Directors to fix their remuneration			
4.	To re-elect Mr. Gil Sharon to the Board			
5.	To re-elect Mr. Moti Nagar to the Board			
6.	To re-elect Mr. Leor Miles to the Board			
7.	To re-elect Dr. Avigdor Shafferman to the Board			
8.	To re-elect Dr. Shmuel Ben Zvi to the Board			
9.	To re-elect Mr. Haim Dor to the Board (if his election becomes effective before the AGM)			

No.	Resolution	Your vote		
		For	Against	Abstain
10.	To authorise the directors to allot equity securities as if article 10A of the Company's articles of association did not apply			
11.	To approve that the remuneration for the role of Chairman of the Board of the Company will be an annual salary of USD 150,000, effective retroactively from 1 January 2026			

Notes:

1. This Form of Proxy to be valid must be completed and signed and must be deposited with MUFG Corporate Markets to its address (at **MUFG Corporate Markets, PXS 1, Central Square, 29 Wellington Street, Leeds LS1 4DL, United Kingdom**) or at the registered office of the Company not less than 48 hours before the time fixed for the meeting.

   Alternatively, you may submit your proxy electronically using the Investor Centre app or at https://uk.investorcentre.mpms.mufg.com/. Shareholders can use this service to vote or appoint a proxy online.

2. In the case of a corporation, this proxy should be under its common seal, or if not so required, under the hand of an officer duly authorised in writing.

3. In the case of joint holders, the signature of any one of them will suffice but the vote of the senior who tenders a vote whether in person or by proxy will be accepted to the exclusion of the votes of the other joint holders and for this purpose, seniority shall be determined by the order in which the names stand on the Company's register of members in respect of the joint holding.

4. Any alteration made in this Form of Proxy should be initialled.

5. To the extent that a personal interest (as defined in Israeli Companies Law) is relevant to the approval of any of the resolutions, by voting using this Form of Proxy you are declaring that you have no personal interest in the approval of such resolution, except a personal interest of which, if applicable, you have specifically informed the Company. In accordance with Israeli Companies Law, a 'personal interest' is deemed to be a personal interest in the engagement contemplated by the resolution, including the interest of certain family relatives and of corporations affiliated to any person having such interest, but excluding a personal interest stemming from the fact of a shareholding in the Company.

6. You are referred to the Notes to the Notice of Annual General Meeting for further information.

Form of Direction

For use by holders of Depositary Interests representing shares on a one-for-one basis in BATM Advanced Communications Ltd. ("BATM") in respect of the Annual General Meeting of BATM to be convened on 23 December 2026 at 12.00 p.m. Israel-time (10.00 a.m. UK-time) at the Company's offices at 4 Ha'harash Street, Nave Ne'eman Industrial Area, building E, 12th floor, Hod Hasharon, Israel

I/We ……

of ……

being a holder of Depositary Interests representing shares in BATM hereby direct MUFG Corporate Markets Trustees (Nominees) Limited, the Depositary, to vote for me/us and on my/our behalf in person or by proxy at the Annual General Meeting of BATM to be held on the above date (and at any adjournment thereof) as directed by an "X" in the appropriate box opposite the resolution. **If no indication is given, you will be deemed as instructing the Depositary to abstain from voting.**

No.	**Resolution**	**Your vote**		
		For	**Against**	**Abstain**
1.	To receive the annual accounts and directors' and auditor's reports thereon			
2.	To approve the report of the Remuneration Committee			
3.	To re-appoint the auditors of the Company and authorise the Board of Directors to fix their remuneration			
4.	To re-elect Mr. Gil Sharon to the Board			
5.	To re-elect Mr. Moti Nagar to the Board			
6.	To re-elect Mr. Leor Miles to the Board			
7.	To re-elect Dr. Avigdor Shafferman to the Board			
8.	To re-elect Dr. Shmuel Ben Zvi to the Board			
9.	To re-elect Mr. Haim Dor to the Board (if his election becomes effective before the AGM)			
10.	To authorise the directors to allot equity securities as if article 10A of the Company's articles of association did not apply			

No.	Resolution	Your vote		
		For	Against	Abstain
11.	To approve that the remuneration for the role of Chairman of the Board of the Company will be an annual salary of USD 150,000, effective retroactively from 1 January 2026			

Signature: …….. Date: ……

Notes:

1. To be effective, this Form of Direction and the power of attorney or other authority (if any) under which it is signed, or a notarised or otherwise certified copy of such power of attorney, must be deposited at MUFG Corporate Markets, PXS 1, Central Square, 29 Wellington Street, Leeds LS1 4DL, United Kingdom not later than 72 hours before the time appointed for holding the meeting.
2. Any alterations made to this Form of Direction should be initialled.
3. In the case of a corporation, this Form of Direction should be given under its common seal or under the hand of an officer or attorney duly authorised in writing.
4. Please indicate how you wish your votes to be cast by placing "X" in the boxes provided. On receipt of this form duly signed, you will be deemed to have authorised MUFG Corporate Markets to vote as per your instructions.
5. The Depositary will appoint the Chairman of the meeting as its proxy to cast your votes. The Chairman may also vote or abstain from voting as he or she thinks fit on any other resolution (including amendments to resolutions) that may properly come before the meeting.
6. If a Depositary Interest holder wishes to attend the Annual General Meeting, they should notify MUFG Corporate Markets (the Depositary) accordingly who will issue a Letter of Representation to the Depositary Interest holder giving them authorisation to attend the Annual General Meeting. If any Depositary Interest holder attends the Annual General Meeting without a Letter of Representation, they will only be allowed to enter the Annual General Meeting as a guest. Requests for a Letter of Representation should be made to the Depositary at MUFG Corporate Markets, PXS 1, Central Square, 29 Wellington Street, Leeds LS1 4DL, United Kingdom or by email to Nominee.Enquiries@cm.mpms.mufg.com no later than 72 hours prior to the meeting or any adjourned meeting.
7. To the extent that a personal interest (as defined in Israeli Companies Law) is relevant to the approval of any of the resolutions, by voting using this Form of Direction you are declaring that you have no personal interest in the approval of such resolution, except a personal interest of which, if applicable, you have specifically informed the Company. In accordance with Israeli Companies Law, a 'personal interest' is deemed to be a personal interest in the engagement contemplated by the resolution, including the interest of certain family relatives and of corporations affiliated to any person having such interest, but excluding a personal interest stemming from the fact of a shareholding in the Company.
8. Depositary Interest Holders may also vote through the CREST Proxy Voting Service in accordance with the procedures set out in the CREST manual.
9. You are referred to the Notes to the Notice of Annual General Meeting for further information.

Form of Proxy

For Holders of Shares Listed on the Tel-Aviv Stock Exchange

For use at the Annual General Meeting of BATM Advanced Communications Ltd, Israeli company no. 520042813, to be convened at 12.00 p.m. Israel-time (10.00 a.m. UK-time) on 23 December 2026 at the Company's offices at 4 Ha'harash Street, Nave Ne'eman Industrial Area, building E, 12th floor, Hod Hasharon, Israel

I/We ……

ID / company number ……

being a holder of share(s) of the Company listed on the Tel-Aviv Stock Exchange and entitled to attend and vote hereby appoint ……..…… (the "TASE Member") to vote on my behalf in person or by proxy as indicated below with an "X" at the Annual General Meeting of the Company convened for 23 December 2026 at 12.00 p.m. Israel-time (10.00 a.m. UK-time) and at any adjournment thereof.

Date …… Signed ……

Please indicate how you wish to vote with an "X" in the appropriate box opposite the resolution. If no specific indication as to voting is given, the TASE Member (or his proxy) will vote or abstain from voting at their discretion. The TASE Member (or his proxy) will vote (or abstain from voting) as they think fit in relation to any other matter which is put before the meeting.

No.	**Resolution**	**Your vote**		
		For	**Against**	**Abstain**
1.	To receive the annual accounts and directors' and auditor's reports thereon			
2.	To approve the report of the Remuneration Committee			
3.	To re-appoint the auditors of the Company and authorise the Board of Directors to fix their remuneration			
4.	To re-elect Mr. Gil Sharon to the Board			
5.	To re-elect Mr. Moti Nagar to the Board			
6.	To re-elect Mr. Leor Miles to the Board			
7.	To re-elect Dr. Avigdor Shafferman to the Board			
8.	To re-elect Dr. Shmuel Ben Zvi to the Board			

No.	Resolution	Your vote		
		For	Against	Abstain
9.	To re-elect Mr. Haim Dor to the Board (if his election becomes effective before the AGM)			
10.	To authorise the directors to allot equity securities as if article 10A of the Company's articles of association did not apply			
11.	To approve that the remuneration for the role of Chairman of the Board of the Company will be an annual salary of USD 150,000, effective retroactively from 1 January 2026			

Notes:

1. For this Form of Proxy to be valid, the broker, bank or other nominee company through which the shareholder holds their shares must receive, by no later than 10.00 a.m. (Israel-time) on 16 December 2026, a legible PDF scan of the duly completed and signed Form of Proxy.
2. In the case of a corporation, this proxy should be under its common seal, or if not so required, under the hand of an officer duly authorised in writing.
3. In the case of joint holders, the signature of any one of them will suffice but the vote of the senior who tenders a vote whether in person or by proxy will be accepted to the exclusion of the votes of the other joint holders and, for this purpose, seniority shall be determined by the order in which the names stand on the Company's register of members in respect of the joint holding.
4. The TASE Member or their proxy will appoint the Chairman of the meeting as their proxy to cast your votes. The Chairman may also vote or abstain from voting as he or she thinks fit on any other resolution (including amendments to resolutions) that may properly come before the meeting.
5. Any alteration made in this Form of Proxy should be initialled.
6. To the extent that a personal interest (as defined in Israeli Companies Law) is relevant to the approval of any of the resolutions, by voting using this Form of Proxy you are declaring that you have no personal interest in the approval of such resolution, except a personal interest of which, if applicable, you have specifically informed the Company. In accordance with Israeli Companies Law, a 'personal interest' is deemed to be a personal interest in the engagement contemplated by the resolution, including the interest of certain family relatives and of corporations affiliated to any person having such interest, but excluding a personal interest stemming from the fact of a shareholding in the Company.
7. You are referred to the Notes to the Notice of Annual General Meeting for further information.